Results 11 to 20 of about 101,617 (297)
SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS [PDF]
Trakia Journal of Sciences, 2023 Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are oral antidiabetic agents commonly used for the treatment of type 2 diabetes mellitus. More than ten years of clinical experience with this group of drugs provides evidence of their efficacy and ...
M. Ganeva
doaj +1 more source
Frontiers in Public Health, 2021 Introduction: Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors) are incretin-based oral antidiabetic drugs. Previous studies have shown an association between increased plasma activity of DPP-4 and chronic hepatitis C virus (HCV) infection. Dipeptidyl
Wei-Hao Hsu +13 more
doaj +1 more source
Therapeutic Advances in Drug Safety, 2022 Registration: PROSPERO: CRD42020210645 Introduction: We aimed to assess the safety of dipeptidyl peptidase-4 (DPP-4) inhibitors in older patients with type 2 diabetes with inadequate glycaemic control.
Katharina Doni +8 more
doaj +1 more source
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis [PDF]
Endocrinology and Metabolism, 2021 Background To compare the renal effects of dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors on individual outcomes in patients with type 2 diabetes. Methods We searched electronic databases (MEDLINE, Embase,
Jae Hyun Bae +5 more
doaj +1 more source
Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study [PDF]
Endocrinology and Metabolism, 2016 BackgroundThe use of dipeptidyl peptidase-4 (DPP-4) inhibitors is increasing among renal transplant patients with diabetes. However, the glucose-lowering efficacies of various DPP-4 inhibitors and their effects on blood cyclosporine levels have not been ...
Jaehyun Bae +8 more
doaj +1 more source
Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors [PDF]
, 2022 Aim: The organ protective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors may be beneficial against infectious complications. This real-world study aims to compare the risk of pneumonia and sepsis between SGLT2 inhibitors and dipeptidyl ...
Yu, Shuk Yin +11 more
core +1 more source
DPP-4 inhibitors subgroup analysis. [PDF]
, 2019 DPP-4 inhibitors subgroup analysis.
Li-Jiuan Shen (1447438) +4 more
core +1 more source
PLoS ONE, 2020 Background and objectiveDipeptidyl peptidase-4 (DPP-4) inhibitors have been suggested to have pancreatic beta-cell preserving effect according to studies using homeostatic model of assessment for beta-cell function (HOMA-β).
Masahiro Takahashi +3 more
doaj +1 more source
PLoS ONE, 2020 BACKGROUND:Cisplatin is a highly effective chemotherapeutic agent. However, acute kidney injury (AKI) limits its subsequent use, resulting in poor cancer prognosis.
Takamasa Iwakura +5 more
doaj +1 more source
Diabetology & Metabolic Syndrome, 2017 Background Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium–glucose co-transporter 2 (SGLT2) inhibitors improve hyperglycemia, and the usefulness of co-administration of DPP-4 inhibitors and insulin therapy has been well established.
Hiroshi Nomoto +7 more
doaj +1 more source